HC Wainwright Issues Pessimistic Forecast for Structure Therapeutics (NASDAQ:GPCR) Stock Price

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) had its target price dropped by research analysts at HC Wainwright from $80.00 to $75.00 in a report released on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 193.43% from the company's current price.

GPCR has been the topic of a number of other reports. William Blair initiated coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating on the stock. Citigroup assumed coverage on Structure Therapeutics in a research report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $78.00.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $25.56 on Monday. The business's fifty day moving average price is $20.94 and its two-hundred day moving average price is $26.87. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $62.74. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -34.54 and a beta of -1.69.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Research analysts expect that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds have recently added to or reduced their stakes in GPCR. Barclays PLC lifted its stake in Structure Therapeutics by 64.5% in the third quarter. Barclays PLC now owns 81,138 shares of the company's stock valued at $3,562,000 after buying an additional 31,815 shares during the period. Principal Financial Group Inc. raised its position in shares of Structure Therapeutics by 230.0% during the third quarter. Principal Financial Group Inc. now owns 545,359 shares of the company's stock worth $23,936,000 after purchasing an additional 380,115 shares during the period. JPMorgan Chase & Co. raised its position in shares of Structure Therapeutics by 302.3% during the third quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock worth $1,489,000 after purchasing an additional 25,500 shares during the period. GAMMA Investing LLC raised its position in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after purchasing an additional 1,122 shares during the period. Finally, FNY Investment Advisers LLC bought a new position in shares of Structure Therapeutics during the fourth quarter worth about $40,000. Institutional investors and hedge funds own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.